Moderna CoVid Vax Is Safe & Effective For Young Children

Vidcast:  https://youtu.be/5QsJHn20Clg

 

Ninety-nine percent of children 6 to 12 years of age receiving the Moderna CoVid vaccine produced protective antibodies to the virus. The antibody levels were comparable to those triggered in young adults by vaccination indicating a very strong anti-CoVid immune response. 

 

Moderna reports this data from the randomized, blinded, placebo controlled KidCOVE study involving 4,753 children in the 6 to 12 year group.  The children were given 2 doses of Moderna vaccine one month apart, and these doses were 50 ug each.  This is one-half of the doses used for adult immunization and the same dose used for the boosters in adults.  Antibody levels against CoVid were measured one month following the second vaccine dose.

 

The vaccine was well-tolerated by the children with a safety profile similar to that observed for adults and adolescents.  The majority of adverse events were mild or moderate including fatigue, headache, fever, and injection site pain.  Monitoring for side effects will continue for 12 months after the second shot.

 

Meanwhile, 2 other groups of young children continue to enter the study to provide sufficient numbers for analysis including those 6 months to under 2 years and those 2 to 6 years of age.

 

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-top-line-data-phase-23-study-covid-19/

 

#moderna #vaccine #CoVid #children #sideeffects